Biotech trends in 2024

The biotech industry is reaching new heights in 2024. It’s an exciting time, with significant changes driven by new technology and fresh ideas.

This year, we’re seeing how AI’s applications span across the biopharma landscape, revolutionising everything from drug discovery to treatment repurposing.

RNA technology, a progressive field that leverages genetic material for medicinal purposes, is on the brink of introducing groundbreaking treatments for formidable illnesses such as cancer and HIV. Concurrently, bioprinting is making its mark as a revolutionary approach. Scientists are harnessing 3D printing technologies to fabricate viable living tissues, opening avenues for pioneering developments in organ regeneration and burn treatment.

With all these advancements, there are new challenges, too. The biotech industry faces the imperative challenge of ensuring these advanced technologies are applied responsibly and equitably. The benefits of these scientific achievements must be accessible to all, forging a path towards inclusive health advancements. As 2024 unfolds, it’s poised to be a year that celebrates scientific breakthroughs and emphasises the responsible integration of these innovations into our healthcare systems, steering us towards a future of improved health outcomes for everyone.

Biotech Market Growth and Investment Trends

According to Grandview Research, the global biotech market was worth US$1.55 trillion in 2023, and the firm expects it to grow at a CAGR of 13.96 per cent between 2024 and 2030 to reach a value of US$3.08 trillion. The biotech industry is showing signs of revival, especially in new company launches (IPOs). The early part of the year brought several successful IPOs, each raising around $100 million, a level of activity not seen since 2021. This has brought a wave of optimism to the industry. Yet, there’s some uncertainty, with most successful IPOs being companies that already have drugs in the later stages of testing. This trend indicates that while the biotech market is picking up, it’s mainly open to companies closer to bringing their products to market.

Despite this positive start, it’s still unclear if this trend will last throughout the year. Some experts believe the success could lead to more companies launching IPOs, while others think we might have to wait until the end of 2024 or even 2025 for a real boom. The focus seems to be on companies with more advanced drug developments, signalling a shift towards safer investment choices in the biotech sector for 2024.

Namepicks

A noticeable trend among the emerging startup companies in the biotechnology sector is the incorporation of “Biotech” in both their company and domain names. While this naming strategy provides immediate clarity, it could restrict a company’s future growth or pivots in focus. As businesses evolve and diversify their offerings, a name explicitly tied to ‘biotech ‘may become too narrow, limiting its representation of the company’s full scope and capabilities. 

As observed in our previous article, “The Importance of Branding in Biotech: A Look at Naming and Domain Choice,” the preference for Exact Brand Match (EBM) domains and the prevalent .com domain is evident. These choices are favoured for their global recognition and credibility. They provide a solid foundation for brand identity and digital presence, which is crucial for companies in the rapidly evolving biotech industry.

Entomal

Malaysian startup Entomal pioneers the Entomal Mobile Bio-Conversion (EMBC) System, revolutionising decentralised organic waste management. This innovative system utilises black soldier fly (BSF) larvae within a compact shipping container set up to transform food or organic waste into valuable products like insect protein and fertiliser. The EMBC system incorporates various technologies, machines, equipment, and IoT sensors in a cabin to effectively manage raw food waste.

Entomal’s name likely derives from entomology, the scientific study of insects, reflecting the company’s focus on utilising insects for sustainable waste management and protein production.

Interesting Fact: Entomal’s business includes insect protein production, tapping into the ancient practice of entomophagy. Historically, insects have been integral to human diets for millennia, as evidenced by archaeological finds at prehistoric sites. Entomophagy has been prevalent across various cultures, especially in Africa, Asia, Latin America, and Oceania. In some communities, insects were prized as delicacies for special events; in others, they were a regular part of the daily diet.

The exact brand match domain Entomal.com enhances the company’s online visibility and credibility, making it easier for clients and partners to find and engage with its innovative waste management solutions.

Gate2Brain

Gate2Brain, emerging from a collaboration between IRB Barcelona, UB, and SJD, is a biotech company dedicated to developing treatments that effectively cross biological barriers like the blood-brain barrier. Utilising a patented peptide technology, they focus on creating therapeutics that penetrate the brain’s protective barrier.

Man has dreamed of travelling to the brain for decades, and, in fact, science fiction has dedicated books and films such as Isaac Asimov’s Fantastic Voyage. Gate2Brain’s dream is to improve the health and quality of life of people suffering from central nervous system diseases by improving drug delivery to the brain and treating it.

Dr. Meritxell Teixidó, CEO of Gate2Brain

Interesting Fact: Gate2Brain is notably working on a pioneering treatment for pediatric brain tumours with intact barriers, a condition currently lacking a cure. Presently in regulatory preclinical testing, the company aims to initiate clinical trials with ten children at the San Joan de Déu hospital by 2026.

While incorporating a number into the brand name, as Gate2Brain does, can accentuate the company’s innovative aspect, it may also increase the likelihood of typing errors in online searches. Gate2Brain operates on the exact brand match domain name Gate2Brain.com.

Hera Biotech

Hera Biotech, a USA-based startup, is transforming the women’s health landscape with its potentially life-changing test for early diagnosis and staging of endometriosis. Hera’s initial goal is to commercialise the MetriDx™, a novel, non-surgical method for the definitive and early diagnosis of endometriosis. Endometriosis is the presence of endometrial glands and stromal-like lesions outside the uterus.

Hera Biotech was founded because I realise that there were huge gaps in women health and we needed a company doing more than just working to silence symptoms.

Somer Baburek, CEO

Interesting Fact: In an interview for FemTechword, Hera Biotech’s CEO, Somer, highlights receiving her first investment from a new investor as a pivotal moment of accomplishment and pride. This event symbolised her success in representing Hera Biotech’s innovative work and strategy, paving the way for the company’s clinical advancements and promoting discussions about women’s health and entrepreneurship.

Hera Biotech has secured HeraBiotech.com for its brand presence online. An exact brand match .com name like HeraBiotech.com is the natural choice of most internet users, making their marketing most effective across all channels.

MxT Biotech

MxT Biotech, a South Korean biotechnology startup, specialises in developing groundbreaking microfluidic platforms for cell engineering and immunotherapies. Its standout offering, Hydroporator, represents a leap forward in the field of cellular engineering. This advanced microfluidic platform expedites the discovery, development, and manufacturing of novel cell therapies by introducing various external cargos, such as plasmid DNA, mRNA, proteins, CRISPR-Cas9 RNPs, and nanoparticles, into primary cells.

Interesting Fact: The innovation behind MxT Biotech’s Hydroporator marks a significant advancement in cellular engineering. This technology dramatically speeds up the development of new cell therapies, facilitating the efficient introduction of a wide range of materials into primary cells.

The name “MxT” likely stands for “Microfluidic Technology,” reflecting the company’s focus on microfluidic platforms for cell engineering.

MxT Biotech’s choice to operate under the exact brand match domain MxtBiotech.com reflects its commitment to technological precision and innovation. This domain enhances the company’s online presence, making it more accessible and credible in the biotech community.

RAGE Biotech

Australian startup RAGE Biotech is pioneering the development of novel therapeutics for challenging inflammatory diseases using cutting-edge ribonucleic acid (RNA) technologies. Their unique approach focuses on targeting the receptor for advanced glycation end-products (RAGE) with proprietary RNA therapeutics and peptide technologies.

RAGE Biotech is an example of what is possible when researchers from world-leading universities come together. We are excited to further support the translation of this breakthrough research that will potentially benefit millions of people.

Dr Siro Perez, Head of Life Sciences at IP Group Australia 

Interesting fact: An interesting aspect of RAGE Biotech’s work is their use of splice-switching oligonucleotides (SSOs) to up-regulate a naturally occurring, anti-inflammatory splice form of RAGE (‘esRAGE’) in inflamed tissues. This innovative approach improves the lives of people with chronic inflammatory conditions and has the potential to benefit over 300 million people globally who suffer from various inflammatory diseases.

RAGE Biotech’s use of the exact brand match domain RAGEBiotech.com enhances their online credibility and accessibility, establishing a clear, professional identity crucial for innovation and trust in the biotech industry.

Highlights

An analysis of our list of 50 biotech startups shows a strong preference for .com domains, with 45 companies choosing this extension. This highlights the widespread perception of .com as a reliable and credible domain in the industry. 

31 of these startups have opted for Exact Brand Match (EBM) domains, reflecting the importance they place on brand consistency and ease of online discoverability.

2 companies have included dash in their domain names. Dashes are often included with two word brand names or with added words when the business has to compromise on their domain if the exact brand match name is taken/not within reach. 

While we make every effort to ensure the data on our site is accurate, complete, and up-to-date, we cannot guarantee its reliability. Our data is provided for informational purposes only and should not be relied upon as legal, financial, or other advice. We strongly recommend that you independently verify any information before relying on it.

Premium domain names are an important investment for any brand. If you’re ready to take the plunge and secure a premium domain name for your business, don’t hesitate to reach out to us for assistance. We’re here to help you choose the perfect domain name and get it set up for your brand.

Other resources

Biotech biotechnology branding domain domain name domain names domains naming startup startups startups naming